Patents by Inventor Nancy Eulalie, Sylvain VAN OSSELAER

Nancy Eulalie, Sylvain VAN OSSELAER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11369606
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20220143141
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 12, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20220047593
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 17, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11103506
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20200138813
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20200138814
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 10537573
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20160367554
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: January 20, 2015
    Publication date: December 22, 2016
    Inventors: Brian D KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE